Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Rheumatic heart disease in Timor-Leste school students: an echocardiography-based prevalence study

The rates of RHD in Timor-Leste are among the highest in the world, and prevalence is higher among girls than boys. Community engagement is essential for ensuring follow-up and the effective delivery of secondary prophylaxis.

Research

SToP (See, Treat, Prevent) skin sores and scabies trial: study protocol for a cluster randomised, stepped-wedge trial for skin disease control in remote Western Australia

Skin infection burden in remote Aboriginal communities can be reduced by the See, Treat, Prevent (SToP skin sores and scabies) trial

Research

Qualitative Evaluation of a Complex Intervention to Improve Rheumatic Heart Disease Secondary Prophylaxis

A multifaceted intervention was implemented using quality improvement and chronic care model approaches to improve delivery of penicillin prophylaxis for rheumatic heart disease

Research

Hospital admissions for skin infections among Western Australian children and adolescents from 1996 to 2012

The objective of this study was to describe the occurrence of skin infection associated hospitalizations in children born in Western Australia (WA).

Research

Hospital admissions for skin infections among Western Australian children and adolescents from 1996 to 2012

Skin infections are a significant cause of severe disease, requiring hospitalization in Western Australian children, particularly with Aboriginal children

Research

Clinical outcomes for young people with screening-detected and clinically-diagnosed rheumatic heart disease in Fiji

Young people with screening-detected RHD have worse health outcomes than screen-negative cases in Fiji.

Research

Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015

The burden of cardiovascular diseases (CVDs) remains unclear in many regions of the world.

Research

Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal community

We report the impact on Strongyloides seroprevalence after two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community.

Research

An update on the burden of group A streptococcal diseases in Australia and vaccine development

Asha Jeffrey Bowen Cannon BA MBBS DCH FRACP PhD GAICD FAHMS OAM BSc(Hons) BBus PhD Head, Healthy Skin and ARF Prevention Health Economist